Published in Neuron on September 30, 2004
Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease. J Neurosci (2009) 12.05
Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron (2009) 7.02
Dendritic spine pathology in neuropsychiatric disorders. Nat Neurosci (2011) 4.80
ApoE promotes the proteolytic degradation of Abeta. Neuron (2008) 4.75
A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol (2009) 4.59
Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J Neurosci (2009) 4.50
Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol (2010) 3.64
Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2006) 3.61
Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature (2010) 3.36
Functional alterations in memory networks in early Alzheimer's disease. Neuromolecular Med (2010) 2.77
Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron (2011) 2.67
An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature (2012) 2.67
Amyloid beta induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation. J Neurosci (2010) 2.46
Critical role of CDK5 and Polo-like kinase 2 in homeostatic synaptic plasticity during elevated activity. Neuron (2008) 2.29
Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol (2010) 2.20
Amyloid beta from axons and dendrites reduces local spine number and plasticity. Nat Neurosci (2009) 2.18
Transsynaptic progression of amyloid-β-induced neuronal dysfunction within the entorhinal-hippocampal network. Neuron (2010) 2.10
Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci (2008) 2.01
Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers. Neurobiol Aging (2007) 1.99
Functional abnormalities of the medial temporal lobe memory system in mild cognitive impairment and Alzheimer's disease: insights from functional MRI studies. Neuropsychologia (2007) 1.81
Reassessing the amyloid cascade hypothesis of Alzheimer's disease. Int J Biochem Cell Biol (2008) 1.78
Neuroinflammatory processes in Alzheimer's disease. J Neural Transm (Vienna) (2010) 1.73
Alzheimer's disease: synaptic dysfunction and Abeta. Mol Neurodegener (2009) 1.73
Beta-amyloid modulation of synaptic transmission and plasticity. J Neurosci (2007) 1.68
The amyloid-beta precursor protein: integrating structure with biological function. EMBO J (2005) 1.68
Polymorphism in Alzheimer Abeta amyloid organization reflects conformational selection in a rugged energy landscape. Chem Rev (2010) 1.62
Induction of toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease-related pathology. J Neurosci (2009) 1.59
Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease. NeuroRx (2005) 1.58
Familial Alzheimer's disease mutations alter the stability of the amyloid beta-protein monomer folding nucleus. Proc Natl Acad Sci U S A (2007) 1.55
Dendritic spine dynamics--a key role for kalirin-7. Trends Neurosci (2008) 1.55
Dynamic analysis of amyloid β-protein in behaving mice reveals opposing changes in ISF versus parenchymal Aβ during age-related plaque formation. J Neurosci (2011) 1.53
Glaucoma, Alzheimer's disease, and Parkinson's disease: an 8-year population-based follow-up study. PLoS One (2014) 1.50
A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol (2009) 1.44
Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem (2005) 1.44
Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. J Neuropathol Exp Neurol (2009) 1.39
Is AD a homogeneous nosologic entity? Yes. J Neural Transm (Vienna) (2013) 1.39
RNA-Seq and human complex diseases: recent accomplishments and future perspectives. Eur J Hum Genet (2012) 1.38
Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. Am J Pathol (2007) 1.36
Cannabinoid CB2 receptors in human brain inflammation. Br J Pharmacol (2007) 1.34
Rer1p competes with APH-1 for binding to nicastrin and regulates gamma-secretase complex assembly in the early secretory pathway. J Cell Biol (2007) 1.34
Mitochondrial cholesterol loading exacerbates amyloid beta peptide-induced inflammation and neurotoxicity. J Neurosci (2009) 1.27
The ubiquitin-proteasome system and the autophagic-lysosomal system in Alzheimer disease. Cold Spring Harb Perspect Med (2012) 1.27
Monoacylglycerol lipase is a therapeutic target for Alzheimer's disease. Cell Rep (2012) 1.25
Estrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases. Front Neuroendocrinol (2008) 1.23
Aggregation and catabolism of disease-associated intra-Abeta mutations: reduced proteolysis of AbetaA21G by neprilysin. Neurobiol Dis (2008) 1.23
Amyloid-β as a modulator of synaptic plasticity. J Alzheimers Dis (2010) 1.22
Synaptic activity prompts gamma-secretase-mediated cleavage of EphA4 and dendritic spine formation. J Cell Biol (2009) 1.19
Structural study of metastable amyloidogenic protein oligomers by photo-induced cross-linking of unmodified proteins. Methods Enzymol (2006) 1.18
Targeting Abeta and tau in Alzheimer's disease, an early interim report. Exp Neurol (2009) 1.18
Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. Proc Natl Acad Sci U S A (2007) 1.17
Cystatin C protects neuronal cells from amyloid-beta-induced toxicity. J Alzheimers Dis (2010) 1.17
Aging of the brain, neurotrophin signaling, and Alzheimer's disease: is IGF1-R the common culprit? Neurobiol Aging (2007) 1.16
The exosome secretory pathway transports amyloid precursor protein carboxyl-terminal fragments from the cell into the brain extracellular space. J Biol Chem (2012) 1.16
Age-related loss of synaptophysin immunoreactive presynaptic boutons within the hippocampus of APP751SL, PS1M146L, and APP751SL/PS1M146L transgenic mice. Am J Pathol (2005) 1.15
Molecular mechanisms of the conjugated alpha,beta-unsaturated carbonyl derivatives: relevance to neurotoxicity and neurodegenerative diseases. Toxicol Sci (2007) 1.15
PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease. Psychopharmacology (Berl) (2006) 1.15
Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase Inhibitor. ACS Med Chem Lett (2010) 1.14
Interactions between APP secretases and inflammatory mediators. J Neuroinflammation (2008) 1.14
Aβ oligomers inhibit synapse remodelling necessary for memory consolidation. Neurobiol Aging (2010) 1.14
Dual effect of amino modified polystyrene nanoparticles on amyloid β protein fibrillation. ACS Chem Neurosci (2010) 1.14
Prenatal activation of microglia induces delayed impairment of glutamatergic synaptic function. PLoS One (2008) 1.13
Polymorphism of Alzheimer's Abeta17-42 (p3) oligomers: the importance of the turn location and its conformation. Biophys J (2009) 1.13
Biogenesis of gamma-secretase early in the secretory pathway. J Cell Biol (2007) 1.11
Molecular reorganization of endocannabinoid signalling in Alzheimer's disease. Brain (2011) 1.10
Mesenchymal stem cells enhance autophagy and increase β-amyloid clearance in Alzheimer disease models. Autophagy (2013) 1.09
Memantine lowers amyloid-beta peptide levels in neuronal cultures and in APP/PS1 transgenic mice. J Neurosci Res (2010) 1.08
The detection of microRNA associated with Alzheimer's disease in biological fluids using next-generation sequencing technologies. Front Genet (2013) 1.08
Concordant association of insulin degrading enzyme gene (IDE) variants with IDE mRNA, Abeta, and Alzheimer's disease. PLoS One (2010) 1.07
Hydrogen sulfide attenuates spatial memory impairment and hippocampal neuroinflammation in β-amyloid rat model of Alzheimer's disease. J Neuroinflammation (2012) 1.06
Apolipoprotein E-mimetics inhibit neurodegeneration and restore cognitive functions in a transgenic Drosophila model of Alzheimer's disease. PLoS One (2009) 1.06
Protective mechanisms by cystatin C in neurodegenerative diseases. Front Biosci (Schol Ed) (2011) 1.05
Amyloid plaque formation precedes dendritic spine loss. Acta Neuropathol (2012) 1.04
The therapeutic effects of Rho-ROCK inhibitors on CNS disorders. Ther Clin Risk Manag (2008) 1.04
Upregulation of TREM2 ameliorates neuropathology and rescues spatial cognitive impairment in a transgenic mouse model of Alzheimer's disease. Neuropsychopharmacology (2014) 1.03
CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease. Integr Biol (Camb) (2011) 1.03
First and second generation γ-secretase modulators (GSMs) modulate amyloid-β (Aβ) peptide production through different mechanisms. J Biol Chem (2012) 1.02
Early-onset subicular microvascular amyloid and neuroinflammation correlate with behavioral deficits in vasculotropic mutant amyloid beta-protein precursor transgenic mice. Neuroscience (2007) 1.01
Epidermal growth factor receptor is a preferred target for treating amyloid-β-induced memory loss. Proc Natl Acad Sci U S A (2012) 1.01
Phosphorylation of kinesin light chain 1 at serine 460 modulates binding and trafficking of calsyntenin-1. J Cell Sci (2011) 1.00
Proteinopathy-induced neuronal senescence: a hypothesis for brain failure in Alzheimer's and other neurodegenerative diseases. Alzheimers Res Ther (2009) 1.00
Lateral organization of the postsynaptic density. Mol Cell Neurosci (2011) 0.98
Neuroregeneration in neurodegenerative disorders. BMC Neurol (2011) 0.98
Advances in the pathogenesis of Alzheimer's disease: a re-evaluation of amyloid cascade hypothesis. Transl Neurodegener (2012) 0.98
Modulation of Abeta42 low-n oligomerization using a novel yeast reporter system. BMC Biol (2006) 0.97
A role for calcineurin in Alzheimer's disease. Curr Neuropharmacol (2011) 0.97
Lowering beta-amyloid levels rescues learning and memory in a Down syndrome mouse model. PLoS One (2010) 0.97
Palmitoylation of amyloid precursor protein regulates amyloidogenic processing in lipid rafts. J Neurosci (2013) 0.97
Protection after stroke: cellular effectors of neurovascular unit integrity. Front Cell Neurosci (2014) 0.97
Do different neurons age differently? Direct genome-wide analysis of aging in single identified cholinergic neurons. Front Aging Neurosci (2010) 0.96
Acetylcholine receptors in dementia and mild cognitive impairment. Eur J Nucl Med Mol Imaging (2008) 0.96
Increase in the density of resting microglia precedes neuritic plaque formation and microglial activation in a transgenic model of Alzheimer's disease. Cell Death Dis (2010) 0.96
Impaired regulation of synaptic actin cytoskeleton in Alzheimer's disease. Brain Res Rev (2011) 0.96
Alzheimer's disease: a clinical practice-oriented review. Front Neurol (2012) 0.95
Cystatin C in Alzheimer's disease. Front Mol Neurosci (2012) 0.94
Significant structural but not physiological changes in cortical neurons of 12-month-old Tg2576 mice. Neurobiol Dis (2008) 0.94
Structural correlates of antibodies associated with acute reversal of amyloid beta-related behavioral deficits in a mouse model of Alzheimer disease. J Biol Chem (2009) 0.94
Induction of complement proteins in a mouse model for cerebral microvascular A beta deposition. J Neuroinflammation (2007) 0.94
In vivo calcium imaging of the aging and diseased brain. Eur J Nucl Med Mol Imaging (2008) 0.93
Pyroglutamate-3 amyloid-β deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse models. Am J Pathol (2013) 0.93
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 49.51
Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature (2002) 19.36
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol (2007) 17.69
Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med (2008) 17.09
Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci (2004) 9.73
A beta oligomers - a decade of discovery. J Neurochem (2007) 8.88
Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci (2007) 8.27
Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron (2009) 7.02
Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A (2003) 5.44
α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature (2011) 5.27
Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis. J Neurosci (2006) 4.14
Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron (2003) 4.11
Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol (2006) 3.74
Dopamine covalently modifies and functionally inactivates parkin. Nat Med (2005) 3.43
Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. Proc Natl Acad Sci U S A (2003) 3.36
Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med (2005) 3.28
Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. Am J Pathol (2004) 3.24
Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A (2011) 3.11
Functional alterations in memory networks in early Alzheimer's disease. Neuromolecular Med (2010) 2.77
Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med (2012) 2.77
Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci (2008) 2.77
Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation. J Neurosci (2005) 2.57
A critical function for beta-amyloid precursor protein in neuronal migration revealed by in utero RNA interference. J Neurosci (2007) 2.48
Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study. Neurology (2013) 2.47
The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron (2003) 2.43
Pink1 forms a multiprotein complex with Miro and Milton, linking Pink1 function to mitochondrial trafficking. Biochemistry (2009) 2.38
Soluble Aβ oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci (2011) 2.33
The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain (2010) 2.29
The Notch ligands, Jagged and Delta, are sequentially processed by alpha-secretase and presenilin/gamma-secretase and release signaling fragments. J Biol Chem (2003) 2.22
Purification and characterization of the human gamma-secretase complex. Biochemistry (2004) 2.18
Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett (2004) 2.16
Activity-dependent isolation of the presenilin- gamma -secretase complex reveals nicastrin and a gamma substrate. Proc Natl Acad Sci U S A (2002) 2.16
Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease. Cold Spring Harb Perspect Med (2012) 2.01
Direct and potent regulation of gamma-secretase by its lipid microenvironment. J Biol Chem (2008) 2.00
Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J Biol Chem (2007) 1.95
The mitochondrial intramembrane protease PARL cleaves human Pink1 to regulate Pink1 trafficking. J Neurochem (2011) 1.93
Assembly of the gamma-secretase complex involves early formation of an intermediate subcomplex of Aph-1 and nicastrin. J Biol Chem (2003) 1.83
Depression is associated with low plasma Abeta42 independently of cardiovascular disease in the homebound elderly. Int J Geriatr Psychiatry (2007) 1.81
Secreted APP regulates the function of full-length APP in neurite outgrowth through interaction with integrin beta1. Neural Dev (2008) 1.79
Electron microscopic structure of purified, active gamma-secretase reveals an aqueous intramembrane chamber and two pores. Proc Natl Acad Sci U S A (2006) 1.77
Pink1 Parkinson mutations, the Cdc37/Hsp90 chaperones and Parkin all influence the maturation or subcellular distribution of Pink1. Hum Mol Genet (2007) 1.76
Environmental novelty activates β2-adrenergic signaling to prevent the impairment of hippocampal LTP by Aβ oligomers. Neuron (2013) 1.76
Cryoelectron microscopy structure of purified gamma-secretase at 12 A resolution. J Mol Biol (2008) 1.75
Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am J Pathol (2004) 1.66
Detergent-dependent dissociation of active gamma-secretase reveals an interaction between Pen-2 and PS1-NTF and offers a model for subunit organization within the complex. Biochemistry (2004) 1.61
Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest (2003) 1.59
Inflammation and therapeutic vaccination in CNS diseases. Nature (2002) 1.58
Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease. PLoS Med (2007) 1.55
Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am J Pathol (2002) 1.54
Dynamic analysis of amyloid β-protein in behaving mice reveals opposing changes in ISF versus parenchymal Aβ during age-related plaque formation. J Neurosci (2011) 1.53
Identification of beta-secretase (BACE1) substrates using quantitative proteomics. PLoS One (2009) 1.52
Intraneuronal Abeta42 accumulation in Down syndrome brain. Amyloid (2002) 1.52
Gamma-secretase exists on the plasma membrane as an intact complex that accepts substrates and effects intramembrane cleavage. J Biol Chem (2004) 1.49
Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. Ann Neurol (2006) 1.48
Proteomic profiling of gamma-secretase substrates and mapping of substrate requirements. PLoS Biol (2008) 1.45
gamma-Secretase substrate selectivity can be modulated directly via interaction with a nucleotide-binding site. J Biol Chem (2005) 1.45
A seed for Alzheimer amyloid in the brain. J Neurosci (2004) 1.45
A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol (2009) 1.44
Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem (2005) 1.44
Alternative translation initiation generates a novel isoform of insulin-degrading enzyme targeted to mitochondria. Biochem J (2004) 1.43
Notch and the amyloid precursor protein are cleaved by similar gamma-secretase(s). Biochemistry (2003) 1.42
Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies. Arch Neurol (2011) 1.42
Kinetics of amyloid beta-protein degradation determined by novel fluorescence- and fluorescence polarization-based assays. J Biol Chem (2003) 1.42
Plasma amyloid-β as a predictor of dementia and cognitive decline: a systematic review and meta-analysis. Arch Neurol (2012) 1.37
Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life. Neurobiol Dis (2009) 1.37
Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. Am J Pathol (2007) 1.36
Designed inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulin. PLoS One (2010) 1.35
Physiological regulation of the beta-amyloid precursor protein signaling domain by c-Jun N-terminal kinase JNK3 during neuronal differentiation. J Neurosci (2005) 1.34
Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice. Neurobiol Dis (2003) 1.32
Alpha-synuclein and polyunsaturated fatty acids promote clathrin-mediated endocytosis and synaptic vesicle recycling. Traffic (2008) 1.30
Biochemical and functional interaction of disrupted-in-schizophrenia 1 and amyloid precursor protein regulates neuronal migration during mammalian cortical development. J Neurosci (2010) 1.29
Alternative splicing of human insulin-degrading enzyme yields a novel isoform with a decreased ability to degrade insulin and amyloid beta-protein. Biochemistry (2005) 1.26
Aggregation and catabolism of disease-associated intra-Abeta mutations: reduced proteolysis of AbetaA21G by neprilysin. Neurobiol Dis (2008) 1.23
Inhibition of receptor-mediated endocytosis demonstrates generation of amyloid beta-protein at the cell surface. J Biol Chem (2003) 1.22
gamma-Secretase cleavage and binding to FE65 regulate the nuclear translocation of the intracellular C-terminal domain (ICD) of the APP family of proteins. Biochemistry (2003) 1.22
Decreased catalytic activity of the insulin-degrading enzyme in chromosome 10-linked Alzheimer disease families. J Biol Chem (2007) 1.22
New ELISAs with high specificity for soluble oligomers of amyloid β-protein detect natural Aβ oligomers in human brain but not CSF. Alzheimers Dement (2013) 1.22
Soluble Arctic amyloid beta protein inhibits hippocampal long-term potentiation in vivo. Eur J Neurosci (2004) 1.19
Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations. Arch Neurol (2011) 1.17
LRP promotes endocytosis and degradation, but not transcytosis, of the amyloid-beta peptide in a blood-brain barrier in vitro model. Neurobiol Dis (2008) 1.15
Alzheimer disease in 2020. Cold Spring Harb Perspect Med (2012) 1.15
Aβ oligomers inhibit synapse remodelling necessary for memory consolidation. Neurobiol Aging (2010) 1.14
Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid beta-protein metabolism in mouse models of Alzheimer disease. Neurobiol Dis (2007) 1.13
Functional gamma-secretase complex assembly in Golgi/trans-Golgi network: interactions among presenilin, nicastrin, Aph1, Pen-2, and gamma-secretase substrates. Neurobiol Dis (2003) 1.11
Small non-fibrillar assemblies of amyloid beta-protein bearing the Arctic mutation induce rapid neuritic degeneration. Neurobiol Dis (2005) 1.10
Presenilin-1 exists in both pre- and post-Golgi compartments and recycles via COPI-coated membranes. Traffic (2003) 1.08
Polyunsaturated fatty acids induce alpha-synuclein-related pathogenic changes in neuronal cells. Am J Pathol (2007) 1.08
Toward structural elucidation of the gamma-secretase complex. Structure (2009) 1.07
Altered fatty acid composition of dopaminergic neurons expressing alpha-synuclein and human brains with alpha-synucleinopathies. J Biol Chem (2003) 1.06
Complex N-linked glycosylated nicastrin associates with active gamma-secretase and undergoes tight cellular regulation. J Biol Chem (2002) 1.06
Molecular basis for the thiol sensitivity of insulin-degrading enzyme. Proc Natl Acad Sci U S A (2008) 1.06
Rapid purification of active gamma-secretase, an intramembrane protease implicated in Alzheimer's disease. J Neurochem (2007) 1.05
The ups and downs of Abeta. Nat Med (2006) 1.04
Effects of membrane lipids on the activity and processivity of purified γ-secretase. Biochemistry (2012) 1.03
Small-molecule activators of insulin-degrading enzyme discovered through high-throughput compound screening. PLoS One (2009) 1.03
Isolation of low-n amyloid β-protein oligomers from cultured cells, CSF, and brain. Methods Mol Biol (2011) 1.03
Amyloid beta dimers/trimers potently induce cofilin-actin rods that are inhibited by maintaining cofilin-phosphorylation. Mol Neurodegener (2011) 1.02
Association of SNCA with Parkinson: replication in the Harvard NeuroDiscovery Center Biomarker Study. Mov Disord (2011) 1.01